TY - JOUR
T1 - The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
AU - Bonanno, Laura
AU - Costa, Carlota
AU - Majem, Margarita
AU - Sanchez, Jose Javier
AU - Gimenez-Capitan, Ana
AU - Rodriguez, Ignacio
AU - Vergnenegre, Alain
AU - Massuti, Bartomeu
AU - Favaretto, Adolfo
AU - Rugge, Massimo
AU - Pallares, Cinta
AU - Taron, Miquel
AU - Rosell, Rafael
PY - 2013/10
Y1 - 2013/10
N2 - Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P
AB - Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P
KW - 53BP1
KW - BRCA1
KW - DNA repair
KW - Platinum
KW - Predictive modeling
UR - http://www.scopus.com/inward/record.url?scp=84886734160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886734160&partnerID=8YFLogxK
M3 - Article
C2 - 24197907
AN - SCOPUS:84886734160
VL - 4
SP - 1572
EP - 1581
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 10
ER -